Micro Imaging Technology Strengthens Portfolio with Cellmyx Acquisition

Micro Imaging Technology Expands Its Portfolio with Cellmyx Acquisition

Micro Imaging Technology, Inc. (MIT), a publicly listed company based in California, is excited to announce its recent acquisition of Cellmyx, a prominent player in the aesthetic, cosmetic surgery, and regenerative medicine sectors. This strategic move is set to strengthen MIT's position and expand its market influence.

About Cellmyx and Its Legacy

Founded 25 years ago under the name Millennium Medical Technologies Inc., Cellmyx has become synonymous with quality in the cosmetic surgery field. Its founder, Greg Miles, has dedicated his efforts to manufacturing high-quality medical tools, focusing on a variety of applications including aesthetics and regenerative solutions. The company has made significant strides with its groundbreaking product, intelliFat, designed for regenerative medicine, ensuring a new frontier in this field of research and innovation.

A Synergistic Acquisition

The acquisition comes on the heels of MIT's previous acquisition of SaltMed/SaltFacial, which concluded in late December 2025. By combining resources and expertise from Cellmyx and SaltFacial, MIT aims to reinforce its manufacturing capabilities both nationally and internationally. Cellmyx is renowned for its leadership in autologous adipose grafting and transfer, making it a perfect complement to MIT’s existing product lines.

In early 2023, Cellmyx received FDA clearance for its intelliFat® BOD™ technology (FDA 510(k) clearance K210528, ISO 13485#0136711, MDSAP#0136710), marking a significant achievement in its commitment to enhance patient recovery and healing through innovative uses of adipose tissue. This technology utilizes the patient’s own body fat for various surgical procedures, including orthopedic and cosmetic surgeries, showcasing MIT's dedication to pioneering advancements in healthcare.

The Future of Aesthetic Medicine

The Cellmyx acquisition positions MIT to further explore the aesthetics and regenerative medicine markets, where innovation can drastically improve patient outcomes. With a focus on developing new applications and enhancing existing technologies, MIT is poised to lead the charge in the medical aesthetics field.

Cellmyx's dedication to the advancement of cosmetic surgery and regenerative medicine underscores the company's commitment to quality and innovation. The acquisition is a clear demonstration of MIT's strategy to diversify its offerings and strengthen its foothold in the market.

Commitment to Excellence

MIT is dedicated to not only maintaining its standard of excellence in serving its existing clientele but also in expanding its reach to new customers. The company recognizes the urgent need for innovative solutions in the beauty and health industries and is committed to exploring further opportunities that will positively impact patient care.

As part of this merger, MIT will continue to support its current customers while embracing new advancements in the aesthetic and regenerative medicine sectors. The company aims to bring cutting-edge technologies and solutions to healthcare providers and patients alike, ensuring they have access to the most effective treatments available.

Conclusion

With the acquisition of Cellmyx, Micro Imaging Technology reaffirms its position as an innovator in the medical aesthetics space. The company’s commitment to excellence and patient care remains unwavering as it expands its portfolio, aiming to create a profound impact on the future of aesthetic medicine. As MIT continues to grow and evolve, it looks forward to meeting the challenges of the healthcare landscape and fulfilling its mission to enhance the quality of life through advanced medical technologies.

For more information about Micro Imaging Technology and its new offerings, visit their official websites.